An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients.

Trial Profile

An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Taranabant (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Sep 2009 Trial phase changed from II to II/III as reported by ClinicalTrials.gov.
    • 17 May 2008 Interim results were reported at the 16th European Congress on Obesity.
    • 14 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top